All In MedTech

Device Trial Radar · NCT06158828

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Nov 15, 2024

Primary completion

Sep 15, 2028

Study completion May 31, 2030

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children's Hospital Foundation; Children's Discovery Institute; Hyundai Hope On Wheels
First posted
Dec 6, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.

Conditions

  • AML, Childhood
  • Aml
  • Acute Myeloid Leukemia, Pediatric
  • Acute Myeloid Leukemia

Interventions

  • Rabbit Anti thymocyte globulinDrug

    rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.

  • BusulfanDrug

    Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.

  • FludarabineDrug

    Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.

  • ThiotepaDrug

    Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.

  • MelphalanDrug

    Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.

  • TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graftBiological

    The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.

  • memory-like natural killer cellsBiological

    The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.

  • IL-2Biological

    IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).

  • PlerixaforDrug

    If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).

  • Granulocyte Colony-Stimulating FactorBiological

    G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.

  • CliniMACSDevice

    After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of patients being administered donor-derived ML NK cells following TCR alpha beta depleted haploidentical cell transplantTime frame: From transplant through Day +100
  2. Feasibility of manufacturing and administering donor-derived ML NK cells following TCR alpha beta depleted haploidentical cell transplantTime frame: Through time of ML NK cell infusion (around Day +7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.